ITCI - Intra-Cellular Therapies: A Dramatic Story June, 18 2022 03:24 AM Intra-Cellular Therapies Inc. Intra-Cellular's atypical antipsychotic CAPLYTA has all the makings of a blockbuster. Now in its initial bipolar launch phase, CAPLYTA is succeeding on all three key leading indicators. Intra-Cellular's financial position is a work in process. For further details see: Intra-Cellular Therapies: A Dramatic Story